A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with high-grade glioma (Alliance A221101). A geriatric assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback